SCHEMBL24253538

SCHEMBL24253538

CC(C)c1nc2nccn2cc1O

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.33
ALDH1A1 P00352 8/20 0.33
NPC1 O15118 7/20 0.33
HPGD P15428 7/20 0.33
RAB9A P51151 7/20 0.33
GAA P10253 5/20 0.33
KMT2A Q03164 2/20 0.33
DYRK1A Q13627 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 4/20 0.33
HSD17B10 Q99714 3/20 0.33
SMN1; SMN2 Q16637 4/20 0.31
POLB P06746 1/20 0.31
CYP1A2 P05177 1/20 0.31
TP53 P04637 2/20 0.30
MAPT P10636 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24874238 0.87 KDM4E (0.32) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL18881756 0.81 ALDH1A1 (0.37) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL15423528 0.81 KDM4E (0.34) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL18721670 0.77 KDM4E (0.38) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL25092575 0.77 ALDH1A1 (0.39) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL24253459 0.76 KDM4E (0.33) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL24874283 0.75
SCHEMBL24253455 0.73 DYRK1A (0.36) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL25064768 0.70 KDM4E (0.32) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL15688379 0.69 ALDH1A1 (0.39) KDM4EALDH1A1NPC1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885ALDH1A1 3964/4885NPC1 2066/4885
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 KDM4E 2530/4885ALDH1A1 4181/4885NPC1 2258/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885ALDH1A1 3964/4885NPC1 2066/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885ALDH1A1 3964/4885NPC1 2066/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 KDM4E 2588/4885ALDH1A1 3962/4885NPC1 1934/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885ALDH1A1 3964/4885NPC1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.